

**JANUARY 23-25 2014**

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER, PARIS, FRANCE

CONTROVERSES  
ET ACTUALITÉS EN CHIRURGIE VASCULAIRE

CONTROVERSIES  
& UPDATES  
IN VASCULAR SURGERY



# Can stent graft design influence cardiac outcome?



**Christos D. Liapis, MD, FACS, FRCS**  
**Professor & Chairman**  
**Department of Vascular Surgery**  
**Medical School, University of Athens**



Αγγειοχειρουργική Κλινική Ιατρικής Σχολής  
Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Dept. of Vascular Surgery - University of Athens



# **Faculty Disclosure**

**Christos D. Liapis**

**I have no financial relationships to disclose**




# Short-term vs. long-term MI following EVAR and Open AAA Repair





# Arterial Stiffness and cardiac outcomes


- Arterial stiffness has been correlated with long-term cardiovascular outcomes independent of traditional cardiovascular risk factors (e.g. hypertension, diabetes, obesity, dyslipidemia, smoking)



- Arterial stiffening results in increased pulse pressure, left ventricular hypertrophy, subendocardial ischemia, endothelial dysfunction and cardiac fibrosis


# Pulse wave velocity (PWV) and cardiac outcomes

□ **Pulse wave velocity (PWV):** the gold standard method of arterial stiffness measurement and a strong independent predictor of cardiovascular morbidity and mortality.



□ Therapeutic modalities reducing PWV are associated with less cardiovascular events rate and improved prognosis

# Arterial stiffness in patients with abdominal (AAA) or thoracic aortic aneurysms (TAA)



- ❑ Men with AAA presented with significantly elevated PWV levels compared to age-matched controls
- ❑ Mean blood pressure, AAA diameter and age: independent determinants of PWV in AAA
- ❑ TAA is associated with increased augmentation index



# Arterial stiffness, circulating vascular calcification inhibitors and inflammatory mediators in pts with AAA

	AAA group (N = 108)	CO group (N = 42)	p
hsCRP (mg/L)	5.90 ± 2.05	2.96 ± 1.02	<0.001
WBC (cells/ $\mu$ L)	9870 ± 2231	8850 ± 2001	0.039
TC (mg/dl)	218 ± 31	184 ± 48	0.118
HDL (mg/dl)	42 ± 11	45 ± 13	0.501
LDL (mg/dl)	137 ± 19	113 ± 22	0.098
TG	148 ± 56	130 ± 39	0.319
PWV (m/s)	12.99 ± 3.75	10.03 ± 1.57	<0.001
Osteoprotegerin (pmol/L)	16.11 ± 3.01	12.13 ± 1.98	<0.001
Osteopontin (ng/ml)	54.4 ± 16.05	42.33 ± 13.72	0.047
IL-6 (pg/ml)	5.51 ± 2.42	4.22 ± 1.63	0.038

	B	p
MBP	0.501	<0.001
OPG	0.405	0.022
OPN	0.204	0.272
IL-6	0.251	0.189
AAA diameter	0.348	0.006

- **PWV and hsCRP, WBC, IL-6, Osteoprotegerin** were significantly upregulated in pts with AAA.
- Independent association of PWV with **mean blood pressure, OPG** and **AAA diameter**

**Kadoglou NP, Liapis CD et al.** Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. Regul Pept. 2012



# Arterial Stiffness after EVAR and TEVAR

**Impaired aortic biomechanics may directly increase the rigidity of the arterial wall measured by Pulse Wave Velocity**

**Limited data implicate the adverse impact of endograft implantation on arterial stiffness which is more pronounced in the descending aorta**

**Does the choice of graft affect arterial stiffness?**




**Is there any clinical significance?**




# Changes in arterial stiffness in patients undergoing EVAR and TEVAR

## Computational Fluid Dynamics Ongoing Trial



# Changes in arterial stiffness in patients undergoing AAA repair



❑ Stent-graft implantation (n=48) was associated with significant increase in PWV 6 months following EVAR

❑ Open surgical repair (n=39) of AAA induced modest increase of PWV (median follow-up: 47d)

# EVAR alters cardiac structure and function

**Table 3. Baseline (Pre-Op) Characteristics of Patients and 1-Year (Follow-up) Outcomes After Endovascular Aortic Repair**

Characteristic	Pre-op (n=22)	Follow-up (n=22)	P value
Specific activity scale score	6.0±1.6	5.3±1.9	<0.05
Systolic blood pressure (mmHg)	131±15	131±16	0.953
Diastolic blood pressure (mmHg)	75±8	74±10	0.476
Heart rate (beats/min)	64±9	62±10	0.283
baPWV (cm/s)	1,834±329	1,942±387	<0.05
Inferior vena cava dimension (mm)	12±3	12±2	0.606
LV volume index at end-diastole (ml/m <sup>2.7</sup> )	29.2±4.8	27.2±4.4	<0.05
Left atrial volume index (ml/m <sup>2.7</sup> )	14.0±5.3	16.2±4.7	<0.05
LVEF (%)	68±5	68±5	0.866
IVST at end-diastole (mm)	9.5±2.6	9.8±2.8	0.088
LV PWT at end-diastole (mm)	8.6±1.0	9.0±1.0	0.201
LV PWT at end-systole (mm)	15.0±1.7	14.8±2.4	0.646
DWS	0.42±0.09	0.38±0.10	0.066
LV mass index (g/m <sup>2.7</sup> )	43±11	45±11	<0.05
Relative wall thickness	0.35±0.05	0.37±0.04	<0.05
E/A ratio	0.82±0.21	0.75±0.19	<0.05
Deceleration time of E wave (ms)	249±32	246±47	0.733
E' (cm/s)	7.8±1.5	7.3±1.8	0.060
E/E' ratio	8.5±1.7	8.6±2.1	0.052

EVAR in 22 pts increased baPWV and induced left ventricular hypertrophy, left atrium enlargement and impaired diastolic function



# Differential effects of endograft types on arterial stiffness in patients undergoing EVAR

N=118 pts

Values of PWV and novel biomarkers at baseline and after 12 months

	PTFE group (N=46)		Polyester Woven group (N=72)		P
	Baseline	12 m	Baseline	12 m	
• PWV (m/s)	12.05±2.55	14.87±2.43*	12.63±2.75	16.75±2.88*	0.033
• OPG (pmol/L)	15.18±3.78	10.51±4.46*	15.72±5.02	12.45±4.94	0.048
• IL-8 (pg/ml)	11.27±5.09	17.97±8.1*	10.27±5.02	25.68±11.11*	<0.001
• IL-6 (pg/ml)	3.81±1.51	3.69±1.37	3.89±4.56	3.58±1.50	0.883
• IL-10 (pg/ml)	5.35±1.57	8.39±2.22*	4.36±2.08	7.64±1.52	0.518

PWV, OPG and IL-8 increase was more pronounced in Polyester Woven group compared to PTFE group (p=0.033, p=0.048, p<0.001 respectively)

Under review J Hypertens






# Arterial stiffness and myocardial strain in TEVAR

## PWV and NT-proBNP changes

30 consecutive pts - Preliminary results

	Before Surgery	6 months post TEVAR	P
PWV (m/s)	11.7 (m/s)	15 (m/s)	<0.001



# Conclusions (I)

EVAR is associated with lower perioperative mortality and morbidity rates compared to open surgical repair

This advantage is blunted at long term, mainly due to an increase in cardiovascular complications

**Arterial stiffening together with adverse cardiac function** after **stent graft implantation** may explain this change in the long-term outcome



# Conclusions (II)

There is evidence of :

- increased **arterial stiffness and biomarkers elevation 1-year** after EVAR **related to endograft type** (polyester more than PTFE).
- **increased arterial stiffness and myocardial strain** after TEVAR was observed. The effect of endograft type in the thoracic aorta requires further investigation.



# Conclusions (III)

- Implantation of an endograft although considered to be a minimally invasive procedure may have serious long-term effects on the cardiovascular system and should be included in the risk factors
- Patients with an endograft should have vigorous monitoring and control of blood pressure, lipids etc and life-long follow-up
- Arterial stiffness should be taken into consideration by the industry when designing new endografts







**Thank you for your attention**



Αγγειοχειρουργική Κλινική Ιατρικής Σχολής  
Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Dept. of Vascular Surgery - University of Athens